loading page

Tacrolimus-Induced Systemic Drug Related Intertriginous and Flexural Exanthema after Hematopoietic Stem Cell Transplantation
  • +4
  • Sara Crowell,
  • Kimberly Taylor,
  • Hemalatha Rangarajan,
  • Rolla Abu-Arja,
  • Vinita Pai,
  • Katya Harfmann,
  • Rajinder Bajwa
Sara Crowell
Nationwide Children's Hospital

Corresponding Author:[email protected]

Author Profile
Kimberly Taylor
Nationwide Children's Hospital Department of Pediatric Hematology Oncology and Bone Marrow Transplants
Author Profile
Hemalatha Rangarajan
Nationwide Children's Hospital Department of Pediatric Hematology Oncology and Bone Marrow Transplants
Author Profile
Rolla Abu-Arja
Nationwide Children's Hospital Department of Pediatric Hematology Oncology and Bone Marrow Transplants
Author Profile
Vinita Pai
Nationwide Children's Hospital Department of Pediatric Hematology Oncology and Bone Marrow Transplants
Author Profile
Katya Harfmann
Nationwide Children's Hospital
Author Profile
Rajinder Bajwa
Nationwide Children's Hospital Department of Pediatric Hematology Oncology and Bone Marrow Transplants
Author Profile

Abstract

Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), previously known as “Baboon Syndrome,” is diagnosed if four or more of the following criteria are met: symmetry, involvement of at least one intertriginous zone, erythema of the gluteal, inguinal, or axillary region, systemic exposure to a drug, and lack of systemic toxicity. A first ever case of SDRIFE after HSCT is presented who was initially treated for multiple recurrences of acute skin graft versus host disease. SDRIFE should be considered in the differential diagnosis of refractory GvHD and is easily treatable by avoiding the offending medication